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Introduction {#sec005}
============

The widespread use of antiretroviral therapy (ART) has brought a marked decline in mortality and morbidity of HIV-infected individuals, but concerns have grown regarding the emergence of other chronic diseases associated with extended life expectancies coupled with the long-term effects of HIV disease and its treatment. One of the serious non-AIDS conditions which have increased mortality in the post-ART era is chronic kidney disease (CKD) \[[@pone.0161562.ref001], [@pone.0161562.ref002]\]. Although rapidly progressive HIV-associated nephropathy (HIVAN) has less frequently been seen, nephrotoxicity due to some antiretrovirals (ARV), including tenofovir disoproxil fumarate (TDF), has been well documented \[[@pone.0161562.ref003]--[@pone.0161562.ref007]\].

TDF is rapidly becoming one of the most widely used ARVs in the world \[[@pone.0161562.ref008]--[@pone.0161562.ref010]\]. Although the mechanism of TDF-related nephrotoxicity has not been fully elucidated, it presents with decreased glomerular filtration rate (GFR) and proximal tubular dysfunction \[[@pone.0161562.ref011]\]. TDF nephrotoxicity may be partly irreversible; therefore early detection of renal dysfunction is a key element of the clinical management \[[@pone.0161562.ref012], [@pone.0161562.ref013]\]. The HIV Medicine Association of the Infectious Diseases Society of America (IDSA) recommends twice yearly monitoring of estimated GFR (eGFR), serum phosphate and urinalysis while receiving TDF \[[@pone.0161562.ref007], [@pone.0161562.ref014]\].

On the other hand, frequent laboratory monitoring of serum creatinine (S-Cr) may not be practical in resource-limited settings, and the World Health Organization (WHO) has yet to recommend routine S-Cr testing before and during ART \[[@pone.0161562.ref010]\]. As TDF use has expanded in resource-limited settings, there are limited data on how often renal function is being monitored and the extent of associated nephrotoxicity being observed \[[@pone.0161562.ref010]\].

In this analysis, we evaluated the frequencies of S-Cr measurement before and during TDF use, and the incidence and factors of renal dysfunction while on TDF in a large prospective cohort in the Asia-Pacific region: the TREAT Asia HIV Observational Database (TAHOD) \[[@pone.0161562.ref015]\].

Methods {#sec006}
=======

Two analyses were conducted based on data collected in TAHOD \[[@pone.0161562.ref015]\]. Briefly, TAHOD is an observational study of patients with HIV involving 22 adult treatment centers in 12 countries and territories of varying income levels in Asia. The study was established in 2003 and aims to assess HIV disease natural history in treated and untreated patients in the region. Retrospective and prospective data is collected at each site. Data is transferred to the data management center at the Kirby Institute, Sydney, Australia, twice annually in March and September.

Analysis (i): To determine frequencies of S-Cr monitoring before and during TDF use {#sec007}
-----------------------------------------------------------------------------------

In this analysis, we included TAHOD patients who had ever received TDF as part of an ART regimen consisting of at least three ARVs. Factors associated with rates of S-Cr monitoring (S-Cr rates) were analyzed using a Poisson regression model with random effects on the patient to account for repeated measurements of S-Cr in individual patients. Analysis time began from ART initiation and was censored when TDF was discontinued for more than seven days, at death or the last follow-up date, whichever occurred first. Patients who re-started TDF after seven days did not re-enter the analysis risk set. Time-fixed covariates included in the model were age, weight, CD4 count, viral load (VL) and hepatitis B/C co-infection at ART initiation, mode of HIV exposure, initial ART regimen, prior AIDS defining illnesses (Centers for Disease Control and Prevention \[CDC\] Category C), pre-ART eGFR, and World Bank country income level \[[@pone.0161562.ref016]\]. Time-updated covariates were TDF use, indinavir (IDV) use, high fasting glucose level (FGL) and high blood pressure. High FGL was defined as a single FGL ≥7 mmol/L or ≥126 mg/dL. High blood pressure was defined as a single systolic \>140 mmHg or diastolic \>90 mmHg measurement.

Trends in crude rates of S-Cr testing for each year on TDF were also explored using Poisson regression with follow-up time beginning from TDF initiation.

Analysis (ii): To determine factors associated with time to renal dysfunction on TDF {#sec008}
------------------------------------------------------------------------------------

Patient selection followed the same criteria as per analysis (i). TDF-related renal toxicity was defined as having eGFR reduction of at least 30% of the baseline value and \<60 ml/min/1.73m^2^, or having ART stopped for reported renal toxicity. The eGFR value used to calculate the percentage decline was the value within six months prior to and closest to the date of TDF initiation. In order to include patients without pre-TDF S-Cr assessment, the first S-Cr after TDF initiation was used as the initial eGFR. The eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@pone.0161562.ref017]\]. The analysis risk time began at TDF initiation rather than from the time of overall ART initiation. To account for censored observations, time to renal dysfunction was analyzed using a Cox regression model and stratified by site. Patients were censored at TDF discontinuation of more than seven days, the last follow-up date or death. Covariates included in the model were age at TDF initiation, sex, mode of HIV exposure, pre-TDF weight, pre-TDF eGFR, pre-TDF VL and CD4 count, TDF combination, prior ART exposure, hepatitis B/C co-infection, prior AIDS illnesses, S-Cr assessment in the previous six months, indinavir use, high FGL, high blood pressure, and ART adherence. S-Cr assessment in the previous six months was coded as a time-updated binary variable where "Yes" referred to having at least one S-Cr assessment in the previous 6-month interval, and "No" meant having no assessment in that time period. To construct this covariate, time was calculated as discrete 6-monthly intervals from TDF initiation (e.g., first six months, second six months). Therefore, if a patient's total follow-up time were currently seven months from TDF initiation, the S-Cr assessment covariate for this patient would refer to the time period between month one to six. If the follow-up time were 11 months, the S-Cr covariate would still refer to month one to six. As such, the S-Cr covariate did not vary continuously, but discretely according to the time interval from TDF initiation. ART adherence was collected from the self-reported visual analogue scale (VAS) \[[@pone.0161562.ref018]\], and coded as \<95%, ≥95% or missing.

All regression models were fitted using backward stepwise selection process. Variables significant in the univariate analysis at Wald's test p \<0.10 were chosen for inclusion in the multivariate model. Variables significant at p \<0.05 were considered statistically significant in the final multivariate model. All data management and statistical analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA) and STATA software version 12.1 (STATA Corp., College Station, TX, USA).

Ethics approval for the TAHOD study design, methods, and consent procedures, was granted by the University of New South Wales, Human Research Ethics Committee. Site-specific study governance was granted by site-relevant institutional review boards. Written informed consent was not sought in TAHOD unless required by a site's local institutional review board. Informed consent was waived at some sites as information is collected via an anonymous case report form. All study procedures were developed in accordance with the revised Helsinki Declaration.

Results {#sec009}
=======

The analysis included a total of 2,425 patients from Cambodia, China (including Hong Kong SAR), India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. Patients initiated ART between 1996 and 2013 and contributed to 13,019 person years on ART and 5,368 years on TDF use. [Table 1](#pone.0161562.t001){ref-type="table"} shows patient characteristics of these patients before ART initiation, and the number of patients with ≥2 average S-Cr assessments per year. Of the 2,425 patients, 69% were male with heterosexual exposure as the reported exposure category for HIV infection. The median age was 35 years (interquartile range \[IQR\]: 30--42), median VL was 100,000 copies/mL (IQR: 34,388--270,000) and median CD4 count was 114 cells/μL (IQR: 39--214). Initial ART combinations consisted mainly of nucleoside reverse transcriptase inhibitors (NRTI), plus non-NRTIs (NNRTI; 83%). More than 60% had no hepatitis B or C co-infections or prior AIDS illnesses. Six hundred and twenty seven of the 2,425 patients (26%) had ≥2 S-Cr assessments per year. The proportion was relatively higher after TDF initiation than prior to TDF use (38% vs. 18%, p\<0.001). These characteristics are also reported by country in [S1 Table](#pone.0161562.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0161562.t001

###### Baseline demographics of patients who have ever received TDF.

![](pone.0161562.t001){#pone.0161562.t001g}

                                                      Total (%)                                 [^a^](#t001fn002){ref-type="table-fn"}Number with average S-Cr assessments ≥2 per year [^b^](#t001fn003){ref-type="table-fn"}(%)
  --------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  **Age at ART initiation (years)**                   median 35, IQR (30--42)                   
  ≤30                                                 680 (28.0)                                151 (22.2)
  31--40                                              1,043 (43.0)                              256 (24.5)
  41--50                                              499 (20.6)                                149 (29.9)
  \>50                                                203 (8.4)                                 71 (35.0)
  **Sex**                                                                                       
  Male                                                1,668 (68.8)                              498 (29.9)
  Female                                              757 (31.2)                                129 (17.0)
  **Mode of HIV Exposure**                                                                      
  Heterosexual contact                                1,671 (68.9)                              317 (19.0)
  Homosexual contact                                  452 (18.6)                                203 (44.9)
  Injecting drug use                                  164 (6.8)                                 39 (23.8)
  Other/unknown                                       138 (5.7)                                 68 (49.3)
  **Pre-ART weight (kg)**                             median = 54.9, IQR (48--63.8)             
  ≤55                                                 823 (33.9)                                162 (19.7)
  \>55                                                732 (30.2)                                244 (33.3)
  Missing                                             870 (35.9)                                221 (25.4)
  **Pre-ART viral load (copies/mL)**                  median = 100,000, IQR (34,388--270,000)   
  ≤100,000                                            599 (24.7)                                217 (36.2)
  \>100,000                                           586 (24.2)                                225 (38.4)
  Missing                                             1,240 (51.1)                              185 (14.9)
  **Pre-ART CD4 (cells/μL)**                          median = 114, IQR (39--214)               
  ≤50                                                 634 (26.1)                                129 (20.3)
  51--100                                             311 (12.8)                                66 (21.2)
  101--200                                            519 (21.4)                                155 (29.9)
  \>200                                               561 (23.1)                                204 (36.4)
  Missing                                             400 (16.5)                                73 (18.3)
  **Initial ART Regimen**                                                                       
  NRTI+NNRTI                                          2,014 (83.1)                              402 (20.0)
  NRTI+PI                                             365 (15.1)                                211 (57.8)
  Other                                               46 (1.9)                                  14 (30.4)
  **Hepatitis B co-infection**                                                                  
  Negative                                            1,593 (65.7)                              468 (29.4)
  Positive                                            334 (13.8)                                102 (30.5)
  Not tested                                          498 (20.5)                                57 (11.4)
  **Hepatitis C co-infection**                                                                  
  Negative                                            1,547 (63.8)                              472 (30.5)
  Positive                                            263 (10.8)                                58 (22.1)
  Not tested                                          615 (25.4)                                97 (15.8)
  **Previous AIDS**                                                                             
  No                                                  1,470 (60.6)                              403 (27.4)
  Yes                                                 955 (39.4)                                224 (23.5)
  **Country Income Level**                                                                      
  Low + Lower Middle                                  898 (37.0)                                137 (15.3)
  Upper Middle                                        1,196 (49.3)                              288 (24.1)
  High                                                331 (13.6)                                202 (61.0)
  **Pre-ART eGFR (ml/min per 1.73 m**^**2)**^                                                   
  \<60                                                25 (1.0)                                  15 (60.0)
  ≥60                                                 1166 (48.1)                               470 (40.3)
  Missing                                             1234 (50.9)                               142 (11.5)
  [^c^](#t001fn004){ref-type="table-fn"}**TDF use**                                             
  Prior to TDF initiation                             N/A                                       293 (17.9)
  After TDF initiation                                N/A                                       929 (38.3)

Note:

^a^---Average calculated by the total number of serum creatinine assessments divided by the total follow-up time for each patient.

^b^---Proportion of patients having two serum creatinine assessments divided by the total number of patients in the same category.

^c^---Time-updated variable. The same patient can be counted in both categories.

TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; ART, antiretroviral therapy; IQR, interquartile range; NRTI, nucleos(t)ide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor

Analysis (i): To determine rates of S-Cr monitoring before and during TDF use {#sec010}
-----------------------------------------------------------------------------

[Table 2](#pone.0161562.t002){ref-type="table"} shows results from a Poisson-random effects model for factors associated with S-Cr monitoring after ART initiation. The overall crude rate was 1.41 per person-year (/PY). The rate while receiving TDF was 1.89/PY, which was relatively higher than the rate before receiving TDF of 1.01/PY (p\<0.001). The maximum follow-up time from ART initiation to the censoring date was 16.9 years, and the maximum time from TDF initiation was 9.6 years. The multivariate model showed that after adjusting for significant predictors, the incidence rate ratio (IRR) for S-Cr testing during TDF compared to prior to TDF use was 1.68 (95% confidence interval (CI) 1.62--1.74, p \<0.001). Other factors associated with higher S-Cr monitoring frequencies were injecting drug use (IDU) compared to heterosexual mode of HIV exposure (IRR 1.22, 95% CI 1.08--1.38; p = 0.002), baseline VL \>100,000 compared to ≤100,000 copies/mL (IRR 1.27, 95% CI 1.16--1.38; p \<0.001), PI-based initial regimen compared to NNRTI-based regimen (IRR 1.27, 95% CI 1.16--1.38; p \<0.001), World Bank upper middle-income countries (IRR 1.15, 95% CI 1.06--1.24; p \<0.001) and high-income countries (IRR 2.05, 95% CI 1.83--2.30; p\<0.001) compared to low- and lower middle-income countries, and high FGL compared to FGL below 7 mmol/L or 126 mg/dL (IRR 1.15, 95% CI 1.05--1.25; p = 0.002). Having eGFR prior to ART ≥60 ml/min/1.73m^2^ compared to \<60 ml/mim/1.73m^2^ (IRR 0.72, 95%CI (0.54, 0.95); p = 0.019).

10.1371/journal.pone.0161562.t002

###### Factors associated with rates of serum creatinine monitoring after ART initiation.
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                                                                                                                                                          Univariate   Multivariate                                           
  --------------------------------------------------------------------------------------------------------------- --------- ------- ------ -------------- ------------ -------------- --------- ---------- ------------------ -------------
  **Age at ART initiation (years)**                                                                                                                                                   \<0.001                                 
  ≤30                                                                                                             3769.9    4846    1.29   (1.25, 1.32)   1                                                                   
  31--40                                                                                                          5877.8    8052    1.37   (1.34, 1.40)   1.06         (0.97, 1.15)   0.231                                   
  41--50                                                                                                          2420.6    3903    1.61   (1.56, 1.66)   1.29         (1.16, 1.44)   \<0.001                                 
  51+                                                                                                             951.0     1608    1.69   (1.61, 1.78)   1.24         (1.07, 1.43)   0.003                                   
  **Sex**                                                                                                                                                                                                                     
  Male                                                                                                            8719.6    12918   1.48   (1.46, 1.51)   1                                                                   
  Female                                                                                                          4299.7    5491    1.28   (1.24, 1.31)   0.82         (0.76, 0.89)   \<0.001                                 
  **Mode of HIV Exposure**                                                                                                                                                            \<0.001                                 **0.009**
  Heterosexual contact                                                                                            9598.4    12463   1.30   (1.28, 1.32)   1                                     1                             
  Homosexual contact                                                                                              2077.0    3675    1.77   (1.71, 1.83)   1.52         (1.38, 1.67)   \<0.001   0.95       (0.87, 1.04)       0.304
  Injecting drug use                                                                                              657.5     1004    1.53   (1.44, 1.62)   1.18         (1.02, 1.37)   0.028     **1.22**   **(1.08, 1.38)**   **0.002**
  Other/unknown                                                                                                   686.5     1267    1.85   (1.75, 1.95)   1.43         (1.23, 1.67)   \<0.001   1.02       (0.89, 1.16)       0.800
  **Pre-ART weight (kg)**                                                                                                                                                                                                     
  \>55                                                                                                            3227.3    5731    1.78   (1.73, 1.82)   1                                                                   
  ≤55                                                                                                             4106.6    5662    1.38   (1.34, 1.42)   0.80         (0.73, 0.89)   \<0.001                                 
  Missing                                                                                                         5685.4    7016    1.23   (1.21, 1.26)                                                                       
  **Pre-ART viral load (copies/mL)**                                                                                                                                                                                          
  ≤100000                                                                                                         2793.8    4967    1.78   (1.73, 1.83)   1                                     1                             
  \>100000                                                                                                        2614.8    5370    2.05   (2.00, 2.11)   1.22         (1.10, 1.34)   \<0.001   **1.27**   **(1.16, 1.38)**   **\<0.001**
  Missing                                                                                                         7610.7    8072    1.06   (1.04, 1.08)                                                                       
  **Pre-ART CD4 (cells/μL)**                                                                                                                                                          0.001                                   
  ≤50                                                                                                             3318.4    4702    1.42   (1.38, 1.46)   1                                                                   
  51--100                                                                                                         1690.3    2161    1.28   (1.23, 1.33)   1.01         (0.89, 1.15)   0.848                                   
  101--200                                                                                                        2784.5    4356    1.56   (1.52, 1.61)   1.12         (1.01, 1.25)   0.030                                   
  \>200                                                                                                           2427.3    4116    1.70   (1.64, 1.75)   1.21         (1.09, 1.35)   \<0.001                                 
  Missing                                                                                                         2798.8    3074    1.10   (1.06, 1.14)                                                                       
  **Initial ART Regimen**                                                                                                                                                             \<0.001                                 **\<0.001**
  NRTI+NNRTI                                                                                                      10842.9   13985   1.29   (1.27, 1.31)   1                                     1                             
  NRTI+PI                                                                                                         1903.6    3983    2.09   (2.03, 2.16)   2.03         (1.84, 2.24)   \<0.001   **1.27**   **(1.16, 1.38)**   **\<0.001**
  Other                                                                                                           272.8     441     1.62   (1.47, 1.77)   1.18         (0.91, 1.53)   0.219     0.83       (0.67, 1.02)       0.080
  **Hepatitis B co-infection**                                                                                                                                                                                                
  Negative                                                                                                        8303.4    13200   1.59   (1.56, 1.62)   1                                                                   
  Positive                                                                                                        1676.6    2676    1.60   (1.54, 1.66)   0.93         (0.84, 1.04)   0.190                                   
  Not tested                                                                                                      3039.3    2533    0.83   (0.80, 0.87)                                                                       
  **Hepatitis C co-infection**                                                                                                                                                                                                
  Negative                                                                                                        8389.9    13102   1.56   (1.54, 1.59)   1                                                                   
  Positive                                                                                                        1138.6    1869    1.64   (1.57, 1.72)   0.97         (0.86, 1.10)   0.657                                   
  Not tested                                                                                                      3490.9    3438    0.98   (0.95, 1.02)                                                                       
  **Previous AIDS**                                                                                                                                                                                                           
  No                                                                                                              7714.0    10758   1.39   (1.37, 1.42)   1                                                                   
  Yes                                                                                                             5305.3    7651    1.44   (1.41, 1.47)   1.04         (0.96, 1.12)   0.359                                   
  **Country Income Level**                                                                                                                                                            \<0.001                                 **\<0.001**
  Low + Lower Middle                                                                                              4166.7    4326    1.04   (1.01, 1.07)   1                                     1                             
  Upper Middle                                                                                                    7078.0    10336   1.46   (1.43, 1.49)   1.39         (1.29, 1.51)   \<0.001   **1.34**   **(1.24, 1.45)**   **\<0.001**
  High                                                                                                            1774.7    3747    2.11   (2.04, 2.18)   2.21         (1.97, 2.48)   \<0.001   **2.05**   **(1.83, 2.30)**   **\<0.001**
  **pre-ART eGFR(ml/min per 1.73 m**^**2**^**)**                                                                                                                                                                              
  \<60                                                                                                            105.5     289     2.74   (2.44, 3.07)   1                                     1                             
  ≥60                                                                                                             4539.7    9507    2.09   (2.05, 2.14)   0.75         (0.54, 1.03)   0.071     **0.72**   **(0.54, 0.95)**   **0.019**
  Missing                                                                                                         8374.1    8613    1.03   (1.01, 1.05)                                                                       
  [^d^](#t002fn005){ref-type="table-fn"}**Receiving TDF**                                                                                                                                                                     
  No                                                                                                              7025.1    7098    1.01   (0.99, 1.03)   1                                     1                             
  Yes                                                                                                             5994.2    11311   1.89   (1.85, 1.92)   1.93         (1.86, 2.00)   \<0.001   **1.68**   **(1.62, 1.74)**   **\<0.001**
  [^d^](#t002fn005){ref-type="table-fn"}**Receiving IDV**                                                                                                                                                                     
  No                                                                                                              12706.8   17945   1.41   (1.39, 1.43)   1                                                                   
  Yes                                                                                                             312.5     464     1.49   (1.36, 1.63)   0.95         (0.84, 1.07)   0.388                                   
  [^a^](#t002fn002){ref-type="table-fn"}^,^[^d^](#t002fn005){ref-type="table-fn"}**High fasting glucose level**                                                                                                               
  No                                                                                                              7566.6    13579   1.79   (1.76, 1.83)   1                                     1                             
  Yes                                                                                                             522.2     998     1.91   (1.80, 2.03)   1.11         (1.02, 1.21)   0.021     **1.15**   **(1.05, 1.25)**   **0.002**
  Missing                                                                                                         4930.5    3832    0.78   (0.75, 0.80)                                                                       
  [^b^](#t002fn003){ref-type="table-fn"}^,^[^d^](#t002fn005){ref-type="table-fn"}**High blood pressure**                                                                                                                      
  No                                                                                                              8047.3    11923   1.48   (1.46, 1.51)   1                                                                   
  Yes                                                                                                             1429.3    2379    1.66   (1.60, 1.73)   1.08         (1.02, 1.14)   0.005                                   
  Missing                                                                                                         3542.7    4107    1.16   (1.12, 1.20)                                                                       

Note:

^a^---high fasting glucose defined as ≥7 mmol/L or ≥126 mg/dL.

^b^---High blood pressure defined as systolic \>140 mmHg, or diastolic \>90 mmHg.

^c^---Crude rate, per person-year

^d^---Time-updated variables

Missing values were coded as a separate category and were excluded from test for heterogeneity.

S-Cr, serum creatinine; CI, confidential interval; IRR, incident rate ratio; ART, antiretroviral therapy; NRTI, nucleos(t)ide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; IDV, indinavir.

Crude rates of S-Cr monitoring for each year on TDF are shown in [Table 3](#pone.0161562.t003){ref-type="table"}. The highest rate of 2.06/PYs (95%CI 2.01--2.11) was observed in the first year on TDF. The rates were shown to have a decreasing trend (p \<0.001) as time on TDF increased; however, rates remained above 1.00/PY across all years, suggesting that in this cohort S-Cr was measured, on average, at least annually while receiving TDF.

10.1371/journal.pone.0161562.t003

###### Crude rates of serum creatinine monitoring for each year on TDF.
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  Year on TDF   Person-years of observation   Number of S-Cr assessments   Crude rate (per person-year)   95% CI
  ------------- ----------------------------- ---------------------------- ------------------------------ --------------
  1st           3,041.02                      6,260                        2.06                           (2.01, 2.11)
  2nd           1,270.4                       2,236                        1.76                           (1.69, 1.83)
  3rd           824.6                         1,445                        1.75                           (1.66, 1.85)
  4th           515.41                        781                          1.52                           (1.41, 1.63)
  5th           220.93                        361                          1.63                           (1.47, 1.81)
  6th-10th      121.81                        228                          1.87                           (1.64, 2.13)

TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; CI, confidential interval.

Analysis (ii): To determine factors associated with time to renal dysfunction on TDF {#sec011}
------------------------------------------------------------------------------------

There were 649/2425 patients (27%) whose first S-Cr measurement used to estimate the baseline GFR occurred after TDF initiation. The median delay between TDF initiation and first S-Cr measurement in this subgroup of patients was 5 months (IQR: 1.4--13 months). The total number of patients with renal dysfunction during TDF use was 103/2425 (4.2%) and the crude toxicity rate was 1.75 per 100PYs. During a median time of follow-up of 2.07 (IQR 1.00--3.56 years, 89 met the eGFR criteria of a decline to 60 ml/min/1.73m^2^ with at least 30% reduction from the baseline. The remaining 14 patients were classified according to reported reasons for ARV discontinuation. Factors associated with time to renal dysfunction are shown in [Table 4](#pone.0161562.t004){ref-type="table"}. The multivariate model showed that the older age group of \>50 years (hazard ratio \[HR\] 5.39, 95%CI 2.52--11.50, p \<0.001) had higher risk of developing renal dysfunction compared to those ≤30 years. Patients who took a PI-based regimen at the time of TDF initiation were almost twice as likely to have toxicity compared to those on an NNRTI-based regimen (HR 1.93, 95%CI 1.22--3.07, p = 0.005). Those with pre-TDF eGFR ≥60 ml/min/1.73m^2^ showed a protective effect (HR 0.38, 95%CI, 0.17--0.85, p = 0.018). ART adherence and S-Cr assessment in the previous 6-month interval were not associated with renal dysfunction.

10.1371/journal.pone.0161562.t004

###### Factors associated with time to renal dysfunction during TDF use.
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                                                                                                                                     Univariate   Multivariate                                     
  ----------------------------------------------------------------------------------------------------------- -------- ----- ------- ------------ --------------- --------- ------ --------------- ---------
  Total                                                                                                       5886.6   103   1.75                                                                  
  Age at TDF initiation (years)                                                                                                                                   \<0.001                          
  ≤30                                                                                                         942.9    9     0.95    1                                      1                      
  31--40                                                                                                      2606.6   29    1.11    1.08         (0.51, 2.31)    0.836     1.09   (0.51, 2.34)    0.815
  41--50                                                                                                      1679.7   26    1.55    1.50         (0.69, 3.26)    0.303     1.58   (0.73, 3.44)    0.248
  51+                                                                                                         657.4    39    5.93    5.81         (2.75, 12.26)   \<0.001   5.39   (2.52, 11.50)   \<0.001
  Sex                                                                                                                                                                                              
  Male                                                                                                        3983.7   78    1.96    1                                                             
  Female                                                                                                      1902.9   25    1.31    0.76         (0.47, 1.21)    0.249                            
  Mode of HIV Exposure                                                                                                                                            0.069                            
  Heterosexual contact                                                                                        4120.9   81    1.97    1                                                             
  Homosexual contact                                                                                          1202.7   10    0.83    0.35         (0.15, 0.79)    0.011                            
  Injecting drug use                                                                                          291.7    4     1.37    0.75         (0.25, 2.23)    0.599                            
  Other/unknown                                                                                               271.2    8     2.95    1.10         (0.51, 2.40)    0.800                            
  Pre-TDF Weight (kg)                                                                                                                                                                              
  ≤55                                                                                                         2012.8   35    1.74    1                                                             
  \>55                                                                                                        2907.0   49    1.69    0.92         (0.59, 1.44)    0.716                            
  Missing                                                                                                     966.7    19    1.97                                                                  
  Pre-TDF eGFR (ml/min 1.73 m^2^)                                                                                                                                                                  
  \<60                                                                                                        68.5     8     11.69   1                                      1                      
  ≥60                                                                                                         3678.9   62    1.69    0.19         (0.09, 0.41)    \<0.001   0.38   (0.17, 0.85)    0.018
  Missing                                                                                                     2139.2   33    1.54                                                                  
  Pre-TDF viral load (copies/mL)                                                                                                                                                                   
  \<5000                                                                                                      1915.3   31    1.62    1                                                             
  ≥5000                                                                                                       2087.0   30    1.44    0.90         (0.52, 1.58)    0.718                            
  Missing                                                                                                     1884.2   42    2.23                                                                  
  Pre-TDF CD4 (cells/μL)                                                                                                                                          0.208                            
  ≤50                                                                                                         553.0    15    2.71    1                                                             
  51--100                                                                                                     409.2    6     1.47    0.54         (0.21, 1.41)    0.210                            
  101--200                                                                                                    1012.8   16    1.58    0.52         (0.25, 1.08)    0.078                            
  201+                                                                                                        3270.0   53    1.62    0.53         (0.29, 0.98)    0.043                            
  Missing                                                                                                     641.5    13    2.03                                                                  
  TDF combination                                                                                                                                                 0.011                            
  NNRTI                                                                                                       4210.9   66    1.57    1                                      1                      
  PI                                                                                                          1490.0   34    2.28    1.99         (1.25, 3.15)    0.003     1.93   (1.22, 3.07)    0.005
  Other                                                                                                       185.7    3     1.62    2.13         (0.64, 7.11)    0.217     2.14   (0.64, 7.20)    0.217
  Prior ARV exposure                                                                                                                                                                               
  No                                                                                                          2154.9   24    1.11    1                                                             
  Yes                                                                                                         3731.6   79    2.12    1.80         (1.09, 2.99)    0.022                            
  Hepatitis B co-infection                                                                                                                                                                         
  Negative                                                                                                    3824.0   60    1.57    1                                                             
  Positive                                                                                                    842.5    16    1.90    1.15         (0.65, 2.03)    0.632                            
  Not tested                                                                                                  1220.0   27    2.21    1.69         (0.90, 3.19)    0.103                            
  Hepatitis C co-infection                                                                                                                                                                         
  Negative                                                                                                    3806.1   57    1.50    1                                                             
  Positive                                                                                                    469.1    10    2.13    1.56         (0.73, 3.32)    0.252                            
  Not tested                                                                                                  1611.4   36    2.23                                                                  
  Previous AIDS                                                                                                                                                                                    
  No                                                                                                          3337.6   47    1.41    1                                                             
  Yes                                                                                                         2549.0   56    2.20    1.47         (0.98, 2.21)    0.064                            
  [^d^](#t004fn005){ref-type="table-fn"}Creatinine assessment in the previous 6 months                                                                                                             
  No                                                                                                          2256.2   29    1.29    1                                                             
  Yes                                                                                                         3630.4   74    2.04    1.27         (0.78, 2.09)    0.336                            
  [^a^](#t004fn002){ref-type="table-fn"}^,^[^d^](#t004fn005){ref-type="table-fn"}High fasting glucose level                                                                                        
  No                                                                                                          937.3    16    1.71    1                                                             
  Yes                                                                                                         62.9     3     4.77    2.63         (0.74, 9.37)    0.135                            
  Not tested                                                                                                  4886.4   84    1.72                                                                  
  [^b^](#t004fn003){ref-type="table-fn"}^,^[^d^](#t004fn005){ref-type="table-fn"}High blood pressure                                                                                               
  No                                                                                                          2097.9   33    1.57    1                                                             
  Yes                                                                                                         412.7    8     1.94    1.15         (0.53, 2.53)    0.722                            
  Not tested                                                                                                  3376.0   62    1.84                                                                  
  [^d^](#t004fn005){ref-type="table-fn"}ART adherence                                                                                                                                              
  \<95%                                                                                                       30.8     1     3.25    1                                                             
  ≥95%                                                                                                        2221.2   33    1.49    0.43         (0.06, 3.27)    0.414                            
  Missing                                                                                                     3634.6   69    1.90                                                                  

Note:

^a^---high fasting glucose defined as ≥7 mmol/L or ≥126 mg/dL.

^b^---High blood pressure defined as systolic \>140 mmHg, or diastolic \>90 mmHg.

^c^---Crude rate, per 100 person-years.

^d^---Time-updated variables.

Missing values were coded as a separate category and were excluded from test for heterogeneity.

TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; CI, confidential interval; HR, incident rate ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ARV, antiretroviral agent; IDV, indinavir; ART, antiretroviral therapy.

Discussion {#sec012}
==========

In this study, we evaluated the frequency of S-Cr monitoring during ART in a large cohort of adult HIV-infected individuals in the Asia-Pacific region and described the incidence and prevalence of renal dysfunction after starting TDF. We found S-Cr was assessed at least once a year during ART and more often after starting TDF. Our study also revealed that 4.2% of individuals experienced eGFR decline to \<60 ml/min/1.73m^2^ with \>30% reduction from baseline or had stopped ART for reported TDF-nephrotoxicity with an incidence of 1.75/100PYs. These data support the need for renal function monitoring for patients receiving TDF-containing ART in resource-limited settings.

Previously, a study from Africa showed limited improvement of prognosis in patients receiving regular laboratory monitoring during ART \[[@pone.0161562.ref019]\]. The WHO currently does not recommend baseline or routine monitoring of S-Cr during ART in resource-limited settings, in accordance with the results of the DART trial \[[@pone.0161562.ref009]\]. However, S-Cr was measured regularly in our study sites regardless of country income levels. The possible reason for such routine S-Cr measurement is that the local ART guideline in each country recommends TDF dose reduction when CrCl is \<50 ml/min and TDF switch when CrCl is \<30 ml/min. Even if S-Cr monitoring is not routinely recommended in the guidelies, the indications to modify TDF dosage may encourage physicians to measure S-Cr regularly. Our data provides an important aspect to the feasibility of regular S-Cr monitoring during TDF use in the Asia-Pacific region.

We observed 1.75/100PYs incidence and 4.2% prevalence of renal dysfunction during a median 2.07 years on TDF. The incidence and prevalence in our study were comparable to previous studies \[[@pone.0161562.ref019]--[@pone.0161562.ref023]\]. However, while severe renal dysfunction that requiring TDF discontinuation was rare in most of those studies, 13.6% (14/103) of the patients defined as having renal dysfunction discontinued TDF for the reason of TDF-nephrotoxicity. TDF tends to be discontinued by physicians earlier than the guidelines indicate (CrCl 30 ml/min) to avoid making the renal dysfunction irreversible and deciding to discontinue TDF may be easier if other ARV options are available. The severity and the reversibility of renal function need to be considered before deciding to discontinue TDF. Therefore, more information is needed to establish an optimal indication for TDF discontinuation in order to preserve future renal function and minimize unnecessary ARV changes from a long-term perspective.

We found that older age (\>50 years), lower pre-TDF eGFR (\<60 ml/min/1.73m^2^) and PI-based regimen are associated with higher risk of renal dysfunction in multivariate analysis, all of which were compatible with previous studies and the WHO recommendations for regular S-Cr monitoring \[[@pone.0161562.ref010],[@pone.0161562.ref019]--[@pone.0161562.ref021],[@pone.0161562.ref024]\]. The higher risk in older age and lower pre-TDF eGFR can be explained by the fact that the CKD prevalence rises with age due to the increasing prevalence of risk factors for CKD, such as diabetes and hypertension, and the natural decline of renal function associated with aging \[[@pone.0161562.ref025]\]. For patients on PI-based regimens, the majority of them (48%) used lopinavir-ritonavir (LPVr). Concurrent use of ritonavir and TDF could result in accumulation of TDF and lead to higher risk for TDF-induced nephrotoxicity \[[@pone.0161562.ref024]\]. Since LPVr has been widely used as the second line ART for those who failed the first NNRTI-based ART, TDF-nephrotoxicity may be a cause of concen in that population. We did not find an increased risk in those who had lower CD4 counts, higher plasma viral loads or lower body weight, although those factors are reported to predict renal dysfunction during ART \[[@pone.0161562.ref019]--[@pone.0161562.ref023]\]. The patients in our cohort had lower CD4 counts at ART initiation than those in resource-rich countries and we were not able to compare the risks with a group of high baseline CD4 counts. Since there has been a global shift toward early ART initiation at higher baseline CD4 counts, there may be a limitation in the generalization of our results in this context. In addition, details of the baseline viral loads in almost half of our patients and body weight in 35% were unavailable, which may have affected the power to detect association with renal dysfunction risk. Our results may be useful when we target populations who have more benefit from S-Cr monitoring in resource-limited settings.

Limitations of our study include difficulty in capturing all renal events. Many of the study sites are in resource-limited settings, where the national ART guidelines recommend TDF switch by single test result, and S-Cr was measured approximately twice yearly. Thus, we were not able to utilize secondary confirmatory testing or distinguish between acute and chronic renal dysfunction. In addition, results of urinalysis, electrolytes or other laboratory data to assess tubular function were not collected in TAHOD. These limitations may have affected the classification of renal dysfunction events, which could lead to the underestimation of the renal dysfunction in this study. Moreover, our definition of eGFR decline meant that patients who did not have an eGFR below 60 ml/min/1.73m^2^ were not counted as having renal dysfunction even if the decline was at least 30%. Using this definition could lead to the underestimation of renal dysfunction, however we believe it better relates to the need for TDF discontinuation than the 30% reduction alone. Furthermore, it was not possible to confirm that all renal dysfunction events observed in the study were related to TDF toxicity. Concomitant medications and other drugs that could affect renal function were not collected. Therefore, our results should be interpreted with care.

Conclusion {#sec013}
==========

In conclusion, 4.2% of individuals on TDF---containing ART experienced renal dysfunction defined as eGFR decline to \<60ml/min/1.73m^2^ with \>30% reduction from baseline and age older than 50 years, pre-TDF eGFR \<60 ml/min/1.73m^2^ and PI-based regimen were at greater risk. These data suggest potential benefits in these higher risk groups for renal function monitoring during TDF-containing ART in resource-limited settings. Further studies are needed to assess the optimal interval of renal function monitoring during TDF use.

Supporting Information {#sec014}
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###### Baseline characteristics of TAHOD patients who have ever received TDF by country.

TDF, tenofovir disoproxil fumarate; cART; combination ART, antiretroviral therapy; IQR, interquartile range; AIDS; acquired immune deficiency syndrome; N/A, not applicable.

(XLSX)

###### 

Click here for additional data file.

###### List of institutional review boards in the study sites.

IRB, institutional review board

(XLSX)

###### 

Click here for additional data file.
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